The CHA₂DS₂-VASc score is a validated clinical tool with modest discrimination (c-statistic 0.6-0.7) that reliably identifies low-risk patients with non-valvular atrial fibrillation who do not require anticoagulation.
The CHA₂DS₂-VASc score is a validated tool that refines the earlier CHADS₂ score to better identify low-risk patients with non-valvular atrial fibrillation, guiding shared decision-making for oral anticoagulation.
The CHA₂DS₂-VASc score is a validated clinical tool for estimating the annual risk of thromboembolic and ischemic stroke in patients with non-valvular atrial fibrillation. It was developed among patients not taking anticoagulation. It refines the earlier CHADS₂ score by incorporating additional risk factors to identify low-risk patients who may not require anticoagulation. The score guides shared decision-making regarding oral anticoagulation.
Rahul Aggarwal (Wed,) conducted a review in Non-valvular atrial fibrillation. CHA₂DS₂-VASc score vs. CHADS₂ score / CHA₂DS₂-VA score was evaluated on 1-year thromboembolic and ischemic stroke risk. The CHA₂DS₂-VASc score is a validated clinical tool with modest discrimination (c-statistic 0.6-0.7) that reliably identifies low-risk patients with non-valvular atrial fibrillation who do not require anticoagulation.